Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) dropped 4.7% during trading on Monday . The company traded as low as $18.81 and last traded at $18.75. Approximately 93,152 shares were traded during mid-day trading, a decline of 74% from the average daily volume of 354,276 shares. The stock had previously closed at $19.66.
Wall Street Analysts Forecast Growth
ETON has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Friday, September 26th. Zacks Research upgraded Eton Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, October 7th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Eton Pharmaceuticals in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $29.67.
Check Out Our Latest Stock Report on Eton Pharmaceuticals
Eton Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.16 and a current ratio of 1.77. The company has a market capitalization of $497.07 million, a price-to-earnings ratio of -115.88 and a beta of 1.16. The firm has a 50-day simple moving average of $18.08 and a two-hundred day simple moving average of $16.33.
Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.09). The business had revenue of $18.93 million during the quarter, compared to analyst estimates of $16.71 million. Eton Pharmaceuticals had a negative net margin of 7.10% and a negative return on equity of 0.73%. On average, sell-side analysts anticipate that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current fiscal year.
Insider Transactions at Eton Pharmaceuticals
In related news, CFO James R. Gruber sold 39,082 shares of Eton Pharmaceuticals stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $16.16, for a total value of $631,565.12. Following the completion of the transaction, the chief financial officer directly owned 205,299 shares in the company, valued at approximately $3,317,631.84. This trade represents a 15.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 16.03% of the company's stock.
Hedge Funds Weigh In On Eton Pharmaceuticals
A number of institutional investors and hedge funds have recently made changes to their positions in ETON. Ameritas Investment Partners Inc. purchased a new position in Eton Pharmaceuticals in the second quarter worth approximately $37,000. Legal & General Group Plc acquired a new stake in shares of Eton Pharmaceuticals in the 2nd quarter valued at $41,000. AlphaQuest LLC purchased a new stake in shares of Eton Pharmaceuticals during the 1st quarter worth $53,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Eton Pharmaceuticals during the second quarter worth $87,000. Finally, Quantbot Technologies LP purchased a new position in Eton Pharmaceuticals in the first quarter valued at $101,000. 27.86% of the stock is owned by institutional investors and hedge funds.
Eton Pharmaceuticals Company Profile
(
Get Free Report)
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eton Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.
While Eton Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
